Lilly had first indicated in August that the tirzepatide shortage would be resolved soon, two months before the FDA's initial decision that it was resolved.

(HealthDay News) — After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without diabetes ...